Cerus Corporation (NASDAQ:CERS) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

5 years ago

Cerus Corporation (NASDAQ:CERS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 5, 2019, Cerus Corporation (the Company) held its 2019 Annual Meeting of Stockholders (the Annual Meeting). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is set forth in the Companys definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2019 (the Proxy Statement).

Proposal 1

The Companys stockholders elected each of the two nominees named below to the Board of Directors to serve until the 2022 Annual Meeting of Stockholders or until her respective successor has been duly elected and qualified.

3,345,593

10,219,245

No other matters were submitted for stockholder action at the Annual Meeting.

About Cerus Corporation (NASDAQ:CERS)

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.